comprehensive -WSS

comprehensive

author：knowledge 2025-09-03 11:51:15 - browse：1

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Trump got a 'target letter.' What is one and what does it mean?

focus

WSS

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

Health and fitness trackers are measuring the wrong things

'Reaching a detente': STAT's Helen Branswell on covering Covid

Risky weight loss products often used by teens globally, per study

Man who had jail sentence commuted by Trump arrested again

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

focus

comprehensive

focus

New air purifier tech could be key to improving indoor air quality

Health and fitness trackers are measuring the wrong things

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why some people catch Covid but never get sick

Affirmative action in medical school literally saved lives

Doulas covered by Medicaid under New York's new plan

Wildfire smoke exposes gaps in outdoor worker protections

Caregivers of transplant patients call for more support, training

Malaria cases in Florida and Texas: Here’s what you need to know

TikTok cracks down on users posting about weight loss drugs

focus

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Norman Reedus' Daryl Dixon

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Idaho abortion case may prompt more restrictions in other states

Stanford president to resign after investigation of research

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

focus

hotspot

focus

focus